Neomorph is building a leading protein degradation entity, focused on 'molecular glue' degraders. Neomorph's mission is to use this technology to solve critical problems in human health with the discovery and development of innovative new medicines against 'undruggable targets.'
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/22/20 | $109,000,000 | Series A |
Deerfield Management Company, L.P. | undisclosed |
